Presented by: Lars Nilsson, Ph.D., Lund University, and Christoph Johann, Ph.D., Wyatt Technology
Presented Live: February 24, 2021
The analysis of aggregates of therapeutic proteins is crucial to ensure efficacy and patient safety. Typically, the analysis is performed in the finished formulation to ensure that aggregates are not present. An important question is, however, what happens to therapeutic proteins, with regard to oligomerization and aggregation, after they have been administrated intravenously.
This webinar features a demonstration of the separation of whole blood, plasma, and serum using asymmetric-flow field-flow fractionation (AF4) with a minimum of sample pre-treatment. The analysis of therapeutic antibodies in blood plasma using AF4 with fluorescence and surface plasmon resonance (SPR) detection is demonstrated in pre-clinical research with further potential for use in clinical trials, following implementation of appropriate quality systems. The results show the suitability and strength of AF4 for blood protein analysis and opens new important routes for the analysis and characterization of therapeutic proteins in blood.